Post by
TanzaniteMotherLode on Mar 10, 2020 7:02am
Another good yahoo post
Heat Biologics is not just a CV play. Even without that massive upside opportunity for shareholder value, the partnership with Bristol Myers Squib on small cell lung cancer is progressing is very promising as it goes to phase 2 trials. I wouldn't be surprised if this is bought out soon just for their proprietary technology. The TCAP - t-cell activation platform is fast, cost effective and through their technology - the solutions are fully scalable and off-the shelf is the desired route for quick treatment and ramping supply to meet demand. Their solutions impact cancer, sars type viruses, malaria defence etc. I see a number of vaccines hitting the market over the years and this is a very attractive buyout candidate (although I prefer they keep going it on their own to maximize shareholder value for true longs).
the management team is proactive and will be out in investors conferences like New York in just under 3 weeks, as well as on TV and other press. The collaboration with the University of Miami will be on the forefront.
the ceo built a company - TyrxPharma which was soldto Medtronic in the past. this is a solid long term investment.